Search

Our systems are now restored following recent technical disruption, and we’re working hard to catch up on publishing. We apologise for the inconvenience caused. Find out more: https://www.cambridge.org/universitypress/about-us/news-and-blogs/cambridge-university-press-publishing-update-following-technical-disruption

Skip to main content Accessibility help

Home
Search

Only show content I have access to (0)

Chapters (1)

Last 3 years (1)

From year:

To year:

Apply

Medicine (1)

cytoreductive surgery

Cambridge University Press (1)

View selected items
Save to my bookmarks
Export citations
Download PDF (zip)
Save to Kindle
Save to Dropbox
Save to Google Drive
Save content to
To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to .

To save content items to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Please be advised that item(s) you selected are not available.
You are about to save
Your Kindle email address

Please provide your Kindle email.

@free.kindle.com @kindle.com (service fees apply)

By using this service, you agree that you will only keep content for personal use, and will not openly distribute them via Dropbox, Google Drive or other file sharing services

1 results

Debate 41B - Should Secondary Cytoreductive Surgery be Offered to all Patients that are Surgical Candidates with Optimally Resectable Recurrent Uterine Leiomyosarcoma?
from Section IV - Endometrial Cancer
- By Félix Blanc-Durand, Amandine Maulard, Patricia Pautier
Edited by Dennis S. Chi, Memorial Sloan-Kettering Cancer Center, New York, Nisha Lakhi, Richmond University Medical Center, Staten Island, Nicoletta Colombo, University of Milan-Bicocca
Book:

50 Big Debates in Gynecologic Oncology

Published online:

20 July 2023

Print publication:

03 August 2023, pp 250-252
- Chapter
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation
Summary

Uterine leiomyosarcomas are rare diseases but represent the commonest subtype of uterine sarcomas. For patients with early-stage localized disease, it is well-known that surgery is the most important part of treatment. However, approximately 40% of patients will present recurrent disease with distant metastasis, and for these patients the question arises as to whether they should have secondary cytoreductive surgery or systemic therapy alone. Decision making needs to take various factors into consideration, as only carefully selected patients will benefit from surgery. Patients for whom surgery is most likely to be beneficial are those with small-volume metastatic disease and late recurrences. In contrast, patients with rapidly progressive disease, or those for whom surgery will not achieve complete macroscopic removal, are unlikely to benefit from surgery, which should be avoided.

Search Results

Refine search

Refine search

Actions for selected content:

1 results

Debate 41B - Should Secondary Cytoreductive Surgery be Offered to all Patients that are Surgical Candidates with Optimally Resectable Recurrent Uterine Leiomyosarcoma?

Summary

Search Results

Refine search

Refine search

Actions for selected content:

Save Search

1 results

Debate 41B - Should Secondary Cytoreductive Surgery be Offered to all Patients that are Surgical Candidates with Optimally Resectable Recurrent Uterine Leiomyosarcoma?

Summary